Jeremey Levin

Phase III Trial of Casopitant, a Novel Neurokinin-1 Receptor Antagonist, for the Prevention of Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy

Jørn Herrstedt, Wichit Apornwirat, Ahmed Shaharyar et al. · Journal of Clinical Oncology · 2009 · 71 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase II Study to Evaluate the Safety and Efficacy of the Oral Neurokinin-1 Receptor Antagonist Casopitant (GW679769) Administered with Ondansetron for the Prevention of Postoperative and Postdischarge Nausea and Vomiting in High-risk Patients

Neil Singla, Sonia Singla, Frances Chung et al. · Anesthesiology · 2010 · 42 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Multicenter Phase II Study to Evaluate a 28-Day Regimen of Oral Fluorouracil Plus Eniluracil in the Treatment of Patients With Previously Untreated Metastatic Colorectal Cancer

Sridhar Mani, Howard S. Höchster, Thomas Beck et al. · Journal of Clinical Oncology · 2000 · 40 citations

Medicine, Oncology, Pharmacotherapy +14

Randomized, Open-Label, Phase III Study of a 28-Day Oral Regimen of Eniluracil Plus Fluorouracil Versus Intravenous Fluorouracil Plus Leucovorin as First-Line Therapy in Patients With Metastatic/Advanced Colorectal Cancer

Richard L. Schilsky, Jeremey Levin, William H. West et al. · Journal of Clinical Oncology · 2002 · 39 citations

Medicine, Oncology, Pharmacology +14

Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, active-controlled, two arm, parallel group study

Paul J. Hesketh, Oliver Wright, Gerardo Rosati et al. · Supportive Care in Cancer · 2011 · 32 citations

Medicine, Oncology, Pharmacology +16